LINC00152 knockdown also suppresses cell proliferation and tumor growth, and LINC00152 has been shown to directly bind with epidermal growth factor receptor (EGFR), thereby activating phosphoinositide 3-kinase (PI3K)/serine/threonine kinase (AKT) signaling [27]. Here, MARK2 is linked to neoplasm.